Faulty Hip Implants: JnJ pays Rs 25 lakh each to three victims in Uttar Pradesh

Published On 2019-08-24 05:26 GMT   |   Update On 2019-08-24 05:26 GMT

According to Uttar Pradesh Drug Licensing and Control officer A K Jain, the company has given compensation to three patients who had undergone revision surgeries for the faulty implants made by JnJ.


Lucknow: Pharma major Johnson & Johnson(JnJ) has paid Rs 25 lakh each to three victims of its faulty acetabular surface replacement (ASR) hip implants in Uttar Pradesh, officials said.


According to Uttar Pradesh Drug Licensing and Control officer A K Jain, the company has given compensation to three patients who had undergone revision surgeries for the faulty implants made by the company.

Also Read: JnJ hip implants: CDSCO orders compensation of over Rs 2 crore for 2 more patients

The Delhi High Court had in May directed JnJ to make an interim payment of Rs 25 lakh each to the 67 patients who have undergone revision surgeries.

As per a recent media report by PTI, Jain said the Uttar Pradesh Drug Licensing and Control Authority was promptly following such complaints.

Also Read: JnJ Faulty Hip Implants: 7 more patients found fit for compensation

Medical Dialogues had earlier reported that JnJ told the Delhi High Court that it was not withholding payment to those patients who underwent revision surgeries for alleged faulty hip implants made by the company and wanted more than the interim compensation of Rs 25 lakh. The submission by JnJ had come in response to a query by Justice Vibhu Bakhru as to what was it doing in cases where patients want more than the Rs 25 lakh.


Also Read: Not withholding interim compensation from patients who want more: JnJ to HC

Article Source : with inputs

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News